We develop novel therapeutic options for patients with neurological and neurodegenerative diseases leading to severe movement, cognition impairments and death.

Our innovative strategy leverages the recently discovered link between excitotoxicity, a condition commonly associated with neurological disorders, including some rare neurodegenerative diseases, and a metabolic shift in neurons, that leads to severe redox stress and neuronal death.

Our novel, potent and highly selective small molecule PFKFB3 inhibitor demonstrated exceptional safety and preclinical efficacy in models of ischemic stroke and neurodegenerative diseases.
Unmet needs
Excitotoxicity, a pathologic process caused by excessive stimulation by neurotransmitters, is commonly associated with acute nerve cell damage, such as stroke, traumatic brain injury (TBI) and stroke, as well as neurodegenerative diseases, including multiple sclerosis, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), Parkinson's disease, Huntington's disease, and others

In the USA alone, every year about 800 thousand people have a stroke, with this medical condition being a leading cause of disability in the United States. It is estimated that 3.2 million–5.3 million persons in the United States are living with a TBI-related disability.

5.8 million patients with Alzheimer's disease, and 1 million patients with Parkinson's disease seeking for life-saving medications. In most of such cases, the therapeutic options are minimal. An effective neuroprotective agent could bring new hope to millions of patients
Contact us:
42/1, Bolshoy Bulvar str., office 332
121205, Moscow
Skolkovo Innovation Center, Russia
Phone: +7 (495) 116 03 95
E-mail: [email protected]